BR112022018878A2 - Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phd - Google Patents
Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phdInfo
- Publication number
- BR112022018878A2 BR112022018878A2 BR112022018878A BR112022018878A BR112022018878A2 BR 112022018878 A2 BR112022018878 A2 BR 112022018878A2 BR 112022018878 A BR112022018878 A BR 112022018878A BR 112022018878 A BR112022018878 A BR 112022018878A BR 112022018878 A2 BR112022018878 A2 BR 112022018878A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- treatment
- pulmonary
- compounds
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992606P | 2020-03-20 | 2020-03-20 | |
| PCT/US2021/023222 WO2021188938A1 (en) | 2020-03-20 | 2021-03-19 | Phd inhibitor compounds, compositions, and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018878A2 true BR112022018878A2 (pt) | 2022-11-29 |
Family
ID=75639963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018878A BR112022018878A2 (pt) | 2020-03-20 | 2021-03-19 | Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phd |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230159489A1 (https=) |
| EP (1) | EP4121426A1 (https=) |
| JP (1) | JP2023518262A (https=) |
| KR (1) | KR20220156890A (https=) |
| CN (3) | CN121085892A (https=) |
| AR (1) | AR121621A1 (https=) |
| AU (1) | AU2021240044A1 (https=) |
| BR (1) | BR112022018878A2 (https=) |
| CA (1) | CA3176142A1 (https=) |
| CO (1) | CO2022014587A2 (https=) |
| IL (1) | IL296632A (https=) |
| MX (1) | MX2022011392A (https=) |
| PH (1) | PH12022552461A1 (https=) |
| TW (1) | TWI912295B (https=) |
| WO (1) | WO2021188938A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| WO2021117767A1 (ja) | 2019-12-10 | 2021-06-17 | 田辺三菱製薬株式会社 | 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663327A (en) * | 1984-05-23 | 1987-05-05 | Bayer Aktiengesellschaft | 1-heteroaryl-4-aryl-pyrazolin-5-ones |
| DE3443308A1 (de) * | 1984-11-28 | 1986-05-28 | Bayer Ag, 5090 Leverkusen | 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel |
| DE102005019712A1 (de) * | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| DE102006050516A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| DE102006050515A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| DE102006050513A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
| WO2008121861A2 (en) * | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| WO2010005851A1 (en) * | 2008-07-08 | 2010-01-14 | Xenon Pharmaceuticals Inc. | Combination therapy for treating iron disorders |
| MA32976B1 (fr) * | 2008-12-29 | 2012-01-02 | Sanofi Sa | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif |
| CA2894399A1 (en) * | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| EA031647B1 (ru) * | 2013-03-29 | 2019-02-28 | Такеда Фармасьютикал Компани Лимитед | 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd |
| CN106831735B (zh) * | 2017-01-23 | 2019-10-11 | 牡丹江医学院 | 一种治疗骨质疏松的杂环化合物及其制备方法和用途 |
-
2021
- 2021-03-19 EP EP21720874.3A patent/EP4121426A1/en active Pending
- 2021-03-19 JP JP2022556196A patent/JP2023518262A/ja active Pending
- 2021-03-19 MX MX2022011392A patent/MX2022011392A/es unknown
- 2021-03-19 CN CN202511236810.1A patent/CN121085892A/zh active Pending
- 2021-03-19 WO PCT/US2021/023222 patent/WO2021188938A1/en not_active Ceased
- 2021-03-19 PH PH1/2022/552461A patent/PH12022552461A1/en unknown
- 2021-03-19 KR KR1020227036363A patent/KR20220156890A/ko active Pending
- 2021-03-19 AU AU2021240044A patent/AU2021240044A1/en active Pending
- 2021-03-19 TW TW110109980A patent/TWI912295B/zh active
- 2021-03-19 US US17/906,652 patent/US20230159489A1/en active Pending
- 2021-03-19 BR BR112022018878A patent/BR112022018878A2/pt unknown
- 2021-03-19 CA CA3176142A patent/CA3176142A1/en active Pending
- 2021-03-19 CN CN202180034132.4A patent/CN115515948B/zh active Active
- 2021-03-19 CN CN202511236822.4A patent/CN121085893A/zh active Pending
- 2021-03-19 AR ARP210100694A patent/AR121621A1/es unknown
- 2021-03-19 IL IL296632A patent/IL296632A/en unknown
-
2022
- 2022-10-14 CO CONC2022/0014587A patent/CO2022014587A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230159489A1 (en) | 2023-05-25 |
| AU2021240044A1 (en) | 2022-11-17 |
| CN121085893A (zh) | 2025-12-09 |
| JP2023518262A (ja) | 2023-04-28 |
| CN121085892A (zh) | 2025-12-09 |
| KR20220156890A (ko) | 2022-11-28 |
| CN115515948B (zh) | 2025-09-09 |
| CA3176142A1 (en) | 2021-09-23 |
| IL296632A (en) | 2022-11-01 |
| MX2022011392A (es) | 2022-12-15 |
| TW202140442A (zh) | 2021-11-01 |
| CN115515948A (zh) | 2022-12-23 |
| CO2022014587A2 (es) | 2022-10-21 |
| WO2021188938A1 (en) | 2021-09-23 |
| AR121621A1 (es) | 2022-06-22 |
| PH12022552461A1 (en) | 2024-01-22 |
| EP4121426A1 (en) | 2023-01-25 |
| TWI912295B (zh) | 2026-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018877A2 (pt) | Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phd | |
| BR112022018878A2 (pt) | Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phd | |
| JP6526306B2 (ja) | バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法 | |
| BR112023003492A2 (pt) | Composto de fórmula (i), composição farmacêutica e uso do composto | |
| JP2018518537A5 (https=) | ||
| JP2022008860A5 (https=) | ||
| CN107708697B (zh) | 纤维化病治疗剂 | |
| US20180000816A1 (en) | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions | |
| US20220281845A1 (en) | Lysophosphatidic acid receptor 1 (lpar1) inhibitor compounds | |
| WO2005120497A2 (en) | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof | |
| BG63944B1 (bg) | Производни на хидроксиламина, които се използват за повишаване продуцирането на молекулен чаперон исъстав | |
| JP2016522831A (ja) | 炎症を予防および治療するためのクリオピリン阻害剤 | |
| JOP20210329A1 (ar) | مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز | |
| US20180273485A1 (en) | Cannabinoid receptor mediating compounds | |
| JP2015536997A (ja) | カンナビノイド受容体媒介性化合物 | |
| JP2017507915A5 (https=) | ||
| BR112018069930B1 (pt) | Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica | |
| JP2020524178A (ja) | ファルネソイドｘ受容体および可溶性エポキシドヒドロラーゼの二重調節剤 | |
| US20170042890A1 (en) | Methods of reducing decline in vital capacity | |
| KR20220127826A (ko) | 화합물 및 α1-항트립신 결핍의 치료를 위한 이의 용도 | |
| US12605378B2 (en) | Small therapeutic molecules capable of inhibiting the catalytic activity of the main protease enzyme of SARS-CoV-2 | |
| JP2023505598A (ja) | 化合物及びα１－アンチトリプシン欠損症の治療のためのそれらの使用 | |
| JP2009504762A5 (https=) | ||
| CO2023000129A2 (es) | Agonistas de pirazolona del receptor 2 del péptido formilo | |
| JP2019535826A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025027329-5 PROTOCOLO 870250113363 EM 09/12/2025 19:38. |